

# ForPatients

by Roche

Hepatocellular Carcinoma (HCC)

## A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

**Trial Status**

Active, not recruiting

**Trial Runs In**

1 Countries

**Trial Identifier**

NCT04487067 ML42243

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This is a Phase IIIb, one arm, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab + bevacizumab in patients with unresectable HCC who have received no prior systemic treatment.

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

---

**NCT04487067 ML42243**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>=18 Years

**Healthy Volunteers**

No

---